Policy: The ‘thousand-dollar genome’: An ethical exploration

European Journal of Human Genetics

Volumn 21, Issue , 2013, Pages S6-S26

  Dondorp, Wybo J ^a   De Wert, Guido Mwr ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; DNA MICROARRAY; DNA SEQUENCE; ECONOMICS; ETHICS; FEMALE; GENETIC ASSOCIATION; GENOMICS; HUMAN; MALE; MEDICAL ETHICS; NETHERLANDS; PREGNANCY; PRENATAL DIAGNOSIS;

ADULT; ETHICS, MEDICAL; FEMALE; GENOME-WIDE ASSOCIATION STUDY; GENOMICS; HUMANS; MALE; NETHERLANDS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PREGNANCY; PRENATAL DIAGNOSIS; SEQUENCE ANALYSIS, DNA;

EID: 84886671743     PISSN: 10184813     EISSN: 14765438     Source Type: Journal    
DOI: 10.1038/ejhg.2013.73     Document Type: Article

References (109)

1. Service RF: Gene sequencing. The race for the $1000 genome. Science 2006; 311: 1544–1546.
2. Pettersson E, Lundeberg J, Ahmadian A: Generations of sequencing technologies. Genomics 2009; 93: 105–111.
3. Willard HF, Angrist M, Ginsburg GS: Genomic medicine: genetic variation and its impact on the future of health care. Philos Trans R Soc Lond B Biol Sci 2005; 360: 1543–1550.
4. Ginsburg GS, Willard HF: Genomic and personalized medicine: foundations and applications. Transl Res 2009; 154: 277–287.
5. Collins FS, Green ED, Guttmacher AE, Guyer MS: A vision for the future of genomics research. Nature 2003; 422: 835–847.
6. Drmanac R, Sparks AB, Callow MJ et al: Human genome sequencing using unchained base reads on self-assembling DNA nanoarrays. Science 2010; 327: 78–81.
7. Durbin RM, Abecasis GR, Altshuler DL et al: A map of human genome variation from population-scale sequencing. Nature 2010; 467: 1061–1073.
8. Altshuler D, Daly MJ, Lander ES: Genetic mapping in human disease. Science 2008; 322: 881–888.
9. von Bubnoff A: Next-generation sequencing: the race is on. Cell 2008; 132: 721–723.
10. McCarroll SA, Altshuler DM: Copy-number variation and association studies of human disease. Nat Genet 2007; 39: S37–S42.
11. Lango H, Weedon MN: What will whole genome searches for susceptibility genes for common complex disease offer to clinical practice? J Intern Med 2008; 263: 16–27.
12. Newton J: Whole-genome sequencing in children with autism funded by stimulus grant. Medical News Today, 2 October 2009: http://www.medicalnewstoday.com/releases/165898.php.
13. Commissie Genetische Modificatie (COGEM), Commissie Biotechnologie bij Dieren(CBD): Gezondheidsraad: Trendanalyse Biotechnologie 2009. Mondiaal Momentum. Bilthoven: COGEM, 2010.
14. Janssens AC: Why realistic test scenarios in translational genomics research remain hypothetical. Public Health Genomics 2010; 13: 166–168.
15. Hunter DJ, Khoury MJ, Drazen JM: Letting the genome out of the bottle–will we get our wish? N Engl J Med 2008; 358: 105–107.
16. Health Council of the Netherlands: Screening: Between Hope and Hype. The Hague: Health Council of the Netherlands, 2008.
17. Bunnik E, Janssens AC, Schermer M: How attitudes research contributes to overoptimistic expectations of personal genome testing. Am J Bioeth 2009; 9: 23–25.
18. Janssens AC, van Duijn CM: Genome-based prediction of common diseases: advances and prospects. Hum Mol Genet 2008; 17: R166–R173.
19. Sanderson SC, Wardle J, Humphries SE: Public health genomics and genetic test evaluation: the challenge of conducting behavioural research on the utility of lifestylegenetic tests. J Nutrigenet Nutrigenom 2008; 1: 224–231.
20. Gresham D, Dunham MJ, Botstein D: Comparing whole genomes using DNA microarrays. Nat Rev Genet 2008; 9: 291–299, 302.
21. Barrans JD, Allen PD, Stamatiou D, Dzau VJ, Liew CC: Global gene expression profiling
22. end-stage dilated cardiomyopathy using a human cardiovascular-based cDNA microarray. Am J Pathol 2002; 160: 2035–2043.
23. Zimmerman RS, Cox S, Lakdawala NK et al: A novel custom resequencing array for dilated cardiomyopathy. Genet Med 2010; 12: 268–278.
24. Hochstenbach R, van Binsbergen E, Engelen J et al: Array analysis and karyotyping: workflow consequences based on a retrospective study of 36, 325 patients with idiopathic developmental delay in the Netherlands. Eur J Med Genet 2009; 52: 161–169.
25. Miller DT, Adam MP, Aradhya S et al: Consensus statement: chromosomal microarray is a firsttier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. Am J Hum Genet 2010; 86: 749–764.
26. Schwarzbraun T, Obenauf AC, Langmann A et al: Predictive diagnosis of the cancer prone Li-Fraumeni syndrome by accident: new challenges through whole genome array testing. J Med Genet 2009; 46: 341–344.
27. Netzer C, Klein C, Kohlhase J, Kubisch C: New challenges for informed consent through whole genome array testing. J Med Genet 2009; 46: 495–496.
28. Klein C, Lohmann-Hedrich K, Rogaeva E, Schlossmacher MG, Lang AE: Deciphering the role of heterozygous mutations in genes associated with parkinsonism. Lancet Neurol 2007; 6: 652–662.
29. de Wert GMWR: Met het oog op de toekomst. Voortplantingstechnologie, erfelijkheidsonderzoek en ethiek. Thela Thesis. Amsterdam, 1999.
30. Elias S, Annas GJ: Generic consent for genetic screening. N Engl J Med 1994; 330: 1611–1613.
31. European Society of Human Genetics (ESHG): Genetic testing in asymptomatic minors: recommendations of the European Society of Human Genetics. Eur J Hum Genet 2009; 17: 720–721.
32. Health Council of the Netherlands: The Term for Retention of Medical Records. The Hague: Health Council of the Netherlands, 2004.
33. Fitzpatrick JL, Hahn C, Costa T, Huggins MJ: The duty to recontact: attitudes of genetics service providers. Am J Hum Genet 1999; 64: 852–860.
34. Hunter AG, Sharpe N, Mullen M, Meschino WS: Ethical, legal, and practical concerns about recontacting patients to inform them of new information: the case in medical genetics. Am J Med Genet 2001; 103: 265–276.
35. Health Council of the Netherlands: Genetic Screening. The Hague: Health Council of the Netherlands, 1994.
36. Ashley EA, Butte AJ, Wheeler MT et al: Clinical assessment incorporating a personal genome. Lancet 2010; 375: 1525–1535.
37. Almond B: Genetic profiling of newborns: ethical and social issues. Nat Rev Genet 2006; 7: 67–71.
38. Human Genetics Commission: Profiling the Newborn: A Prospective Gene Technology?. London: Human Genetics Commission, 2005.
39. Collins FS: The Language of Life. DNA and the Revolution in Personalized Medicine. New York: Harper, 2010.
40. Henneman L, Poppelaars FA, Ten Kate LP: Evaluation of cystic fibrosis carrier screening programs according to genetic screening criteria. Genet Med 2002; 4: 241–249.
41. De Wert G, Dondorp W: Ethical issues; in Van Vugt JMG, Shulman L (eds): Prenatal Medicine. New York, London: Taylor & Francis, 2006, pp 575–604.
42. Health Council of the Netherlands: Preconception Care: A Good Beginning. The Hague: Health Council of the Netherlands, 2007.
43. de Wert GMWR, de Wachter MAM: Mag ik uw genenpaspoort? Ethische aspecten van dragerschapsonderzoek bij de voortplanting. Baarn: Ambo, 1990.
44. Couzin-Frankel J: Chasing a disease to the vanishing point. Science 2010; 328: 298–300.
45. Pollack A: Firm brings new test to the masses. New York Times, 28 January 2010 http://www.nytimes.com/2010/01/29/business/29gene.html?pagewanted¼all&_r¼0
46. Bell CJ, Dinwiddie DL, Miller NA: Carrier screening of recessive genetic disorders by next generation sequencing; Poster ASHG Congress; 2–6 November 2010; Washington, DC.
47. Department of Health: Our Inheritance, Our Future – Realising the Potential of Genetics in the NHS. London: Department of Health, 2003.
48. Feinberg J: The child’s right to an open future; in Aiken W, Lafollette H (eds): Whose Child? Children’s Rights, Parental Autonomy, and State Power. New Jersey, Littlefield: Adams & Co, 1980, pp 124–153.
49. Robertson S, Savulescu J: Is there a case in favour of predictive genetic testing in young children? Bioethics 2001; 15: 26–49.
50. Nuffield council on Bioethics: Genetics and Behaviour. The Ethical Context. London: Nuffield Council on Bioethics, 2002.
51. President’s Council on Bioethics: The Changing Moral Focus of Newborn Screening. Washington, DC: President’s Council on Bioethics, 2008.
52. Alexander D, van Dyck PC: A vision of the future of newborn screening. Pediatrics 2006; 117: S350–S354.
53. Green NS, Pass KA: Neonatal screening by DNA microarray: spots and chips. Nat Rev Genet 2005; 6: 147–151.
54. Gurwitz D, Fortier I, Lunshof JE, Knoppers BM: Research ethics. Children and population biobanks. Science 2009; 325: 818–819.
55. Tarini BA, Singer D, Clark SJ et al: Parents’ interest in predictive genetic testing for their children when a disease has no treatment. Pediatrics 2009; 124: e432–e438.
56. Health Council of the Netherlands: Neonatal Screening. The Hague: Health Council of the Netherlands, 2005.
57. Botkin JR, Clayton EW, Fost NC et al: Newborn screening technology: proceed with caution. Pediatrics 2006; 117: 1793–1799.
58. Ross LF: Screening for conditions that do not meet the Wilson and Jungner criteria: the case of Duchenne muscular dystrophy. Am J Med Genet A 2006; 140: 914–922.
59. de Wert GM: Neonatale screening: dynamiek en ethiek. Ned Tijdschr Geneeskd 2005; 149: 2841–2843.
60. Wilcken B, Wiley V: Newborn screening. Pathology 2008; 40: 104–115.
61. Anon: Hielprik moet veel meer ziekten opsporen. Medisch Contact, 4 januari 2007.
62. Dutch Forum for Biotechnology & Genetics: Letter to the Predictive Medicine Committee of the Health Council of the Netherlands, 10 January 2008. http://www.forumbg.nl/documenten/brieven/brief-commissie-voorspellende-geneeskunde-gezondheidsraad.
63. Gezondheidsraad: Prenatale screening: Downsyndroom, neuralebuisdefecten, routineechoscopie. Den Haag: Gezondheidsraad, 2001.
64. Bilardo CM, Timmerman E, Pajkrt E, van Maarle M: Increased nuchal translucency in euploid fetuses-what should we be telling the parents? Prenat Diagn 2010; 30: 93–102.
65. Ten Kate LP: Snelle prenatale diagnostiek van chromosomale afwijkingen; beperkingen en mogelijkheden. Ned Tijdschr Geneeskd 2006; 150: 1608–1612.
66. Boormans EM, Birnie E, Oepkes D, Galjaard RJ, Schuring-Blom GH, van Lith JM: Comparison of multiplex ligation-dependent probe amplification and karyotyping in prenatal diagnosis. Obstet Gynecol 2010; 115: 297–303.
67. de Jong A, Dondorp WJ, de Wert GM: Prenatale chromosoomdiagnostiek: breed of smal? Ethische overwegingen bij het testaanbod. Ned Tijdschr Geneeskd 2009; 153: A1060.
68. Sahoo T, Cheung SW, Ward P et al: Prenatal diagnosis of chromosomal abnormalities using array-based comparative genomic hybridization. Genet Med 2006; 8: 719–727.
69. Van den Veyver IB, Beaudet AL: Comparative genomic hybridization and prenatal diagnosis. Curr Opin Obstet Gynecol 2006; 18: 185–191.
70. South ST, Chen Z, Brothman AR: Genomic medicine in prenatal diagnosis. Clin Obstet Gynecol 2008; 51: 62–73.
71. American College of Obstetricians and Gynecologists (ACOG): Invasive prenatal testing for aneuploidy. Obstet Gynecol 2007; 110: 1459–1467.
72. Ogilvie CM, Yaron Y, Beaudet AL: Current controversies in prenatal diagnosis 3: For prenatal diagnosis, should we offer less or more than metaphase karyotyping? Prenat Diagn 2009; 29: 11–14.
73. Wright CF, Burton H: The use of cell-free fetal nucleic acids in maternal blood for noninvasive prenatal diagnosis. Hum Reprod Update 2009; 15: 139–151.
74. Benn PA, Chapman AR: Ethical challenges in providing noninvasive prenatal diagnosis. Curr Opin Obstet Gynecol 2010; 22: 128–134.
75. Shuster E: Microarray genetic screening: a prenatal roadblock for life? Lancet 2007; 369: 526–529.
76. de Jong A, Dondorp WJ, de Die-Smulders CE, Frints SG, de Wert GM: Non-invasive prenatal testing: ethical issues explored. Eur J Hum Genet 2010; 18: 272–277.
77. Darilek S, Ward P, Pursley A et al: Pre- and postnatal genetic testing by arraycomparative genomic hybridization: genetic counseling perspectives. Genet Med 2008; 10: 13–18.
78. Van den Veyver IB, Patel A, Shaw CA et al: Clinical use of array comparative genomic hybridization (aCGH) for prenatal diagnosis in 300 cases. Prenat Diagn 2009; 29: 29–39.
79. Van Zwieten M: The Target of Testing. Dealing with ‘Unexpected’ Findings in Prenatal Diagnosis. Amsterdam: Buyten & Schipperheijn, 2006.
80. de Kort S: Verkeerde routine. 20-weken echo is zoektocht naar alle mogelijke afwijkingen geworden. Medisch Contact 2008; 63: 562–563.
81. Harper J, Coonen E, De Rycke M et al: What next for preimplantation genetic screening (PGS)? A position statement from the ESHRE PGD Consortium Steering Committee. Hum Reprod 2010; 25: 821–823.
82. Health Council of the Netherlands: Pre-implantation Genetic Diagnosis. The Hague: Health Council of the Netherlands, 2006.
83. Vanneste E, Voet T, Melotte C et al: What next for preimplantation genetic screening? High mitotic chromosome instability rate provides the biological basis for the low success rate. Hum Reprod 2009; 24: 2679–2682.
84. Hellani A, Abu-Amero K, Azouri J, El-Akoum S: Successful pregnancies after application of array-comparative genomic hybridization in PGS-aneuploidy screening. Reprod Biomed Online 2008; 17: 841–847.
85. Wilton J: Preimplantation genetic diagnosis: the future; in Harper J (ed): Preimplantation Genetic Diagnosis. Cambridge: CUP, 2009, 2nd edn. pp 274–285.
86. Handyside A: Let parents decide. Nature 2010; 464: 978–979.
87. Gezondheidsraad: Handelingen met geslachtscellen en embryo’s. Den Haag: Centrum voor Ethiek en Gezondheid (CEG), 2003.
88. Robertson JA: The $1000 genome: ethical and legal issues in whole genome sequencing of individuals. Am J Bioeth 2003; 3: W-IF1.
89. Ormond KE, Wheeler MT, Hudgins L et al: Challenges in the clinical application of whole-genome sequencing. Lancet 2010; 375: 1749–1751.
90. Samani NJ, Tomaszewski M, Schunkert H: The personal genome–the future of personalised medicine? Lancet 2010; 375: 1497–1498.
91. Gezondheidsraad: Jaarbericht bevolkingsonderzoek 2006. Den Haag: Gezondheidsraad 2006.
92. Raad voor de Volksgenzondheid en Zorg: Screening en de rol van de overheid. Den Haag: RVZ, 2008.
93. Bovenberg JA: Het Antoni van Leeuwenhoekrecht: pleidooi voor een nieuw grondrecht. Handelingen Nederlandse Juristen-Vereniging 2009; 139: 61–96.
94. Clarke AJ: Prenatal genetic screening. Paradigms and perspectives; in Harper PS, Clarke AJ (eds): Genetics, Society and Clinical Practice. Oxford: Bios Scientific Publishers, 1997, pp 119–140.
95. Andrews LB, Fullarton JE, Holtzman NA, Motulsky AG: Assessing Genetic Risks. Implications for Health and Social Policy. Washington, DC: National Academy Press, 1994.
96. Ross L: Predictive genetic testing for conditions that present in childhood. Kennedy Inst Ethics J 2002; 12: 225–244.
97. Gezondheidsraad: Screening van pasgeborenen op aangeboren stofwisselingsziekten. Den Haag: Centrum voor Ethiek en Gezondheid (CEG), 2003.
98. Health Council of the Netherlands: Care for the Unborn Child. The Hague: Centre for Ethics and Health (CEG), 2009.
99. Berghmans R, De Jong J, Widdershoven G, De Wert G: Dwangmogelijkheden te beperkt. Bescherm foetus tegen verslaafde moeder. Medisch Contact 2009; 64: 77–80.
100. Health Council of the Netherlands: Heredity: Science and Society; On the Possibilities and Limits of Genetic Testing and Gene Therapy. The Hague: Health Council of the Netherlands, 1989.
101. de Wert GMWR, Tibben A: Voorspellend genetisch onderzoek naar de ziekte van Alzheimer: ethische aspecten; in Berghmans RLP, Ter Meulen RHJ, de Wert GMWR (eds): Verdwaald bestaan. Ethiek en dementie. van Gorcum: Assen, 2003, pp 101–131.
102. de Wert GMWR: Ethical aspects of prenatal testing and preimplantation genetic diagnosis for late onset neurogenetic disease: the case of Huntington’s disease; in Evers-Kiebooms G, Zoetewij MW, Harper PS (eds): Prenatal Testing for Late-Onset Neurogenetic Diseases. Oxford: Bios Scientific Publishers, 2002.
103. de Wert GMWR: The transparent embryo. Ethics and politics of pre-implantation genetic diagnosis. Dies Natalis Lecture. 11 January 2008; Maastricht University, Maastricht, 2008.
104. Savulescu J, Kahane G: The moral obligation to create children with the best chance of the best life. Bioethics 2009; 23: 274–290.
105. Pennings G, de Wert G, Shenfield F, Cohen J, Tarlatzis B, Devroey P: ESHRE Task Force on Ethics and Law 13: the welfare of the child in medically assisted reproduction. Hum Reprod 2007; 22: 2585–2588.
106. Holm S: Informed consent and the biobanking of material from children. Genomics Social Policy 2005; 1: 16–26.
107. Hens K, Nys H, Cassiman JJ, Dierickx K: Genetic research on stored tissue samples from minors: a systematic review of the ethical literature. Am J Med Genet A 2009; 149A: 2346–2358.
108. Wald N: Neonatal screening: old dogma or sound principle? Pediatrics 2007; 119: 406–407.
109. Howard HC, Knoppers BM, Borry P: Blurring lines. The research activities of direct-toconsumer genetic testing companies raise questions about consumers as research subjects. EMBO Rep 2010; 11: 579–582.